CALERIE Phase II Ancillary: Metabolic

Hypothesis 1: The decrease in energy expenditure (sedentary and sleeping) will be larger than that expected on the basis of loss of fat-free mass and fat mass even after weight stabilization. Aim 1: Determine the metabolic adaptation after 1 and 2 years of a 25% CR

Hypothesis 2: The metabolic adaptation (what is not accounted by a decrease in FM and FFM) is not entirely accounted by reduced organ/tissue size (liver, spleen, kidney, heart and brain) but is accompanied by reduced activities of the sympathetic and thyroid systems. Aim 2: Assess the contribution of organ sizes and activities of the thyroid and sympathetic systems to the metabolic adaptation. Results will be compared to in vivo and in vitro oxidative phosphorylation (Smith, PI).

Hypothesis 3: A decrease in markers of oxidative stress to lipid (urinary isoprostanes) DNA (strand breaks) in blood and protein (carbonylation and thiol oxidation) in blood and skeletal muscle tissue after 1 and 2 years of CR will be observed. Aim 3: Determine the changes in oxidative stress after 1 and 2 years of 25% CR by measuring urinary isoprostanes, serum carbonyls, DNA damage in nucleated blood cells and protein oxidation (carbonyls and oxidation of cysteine residues) in skeletal muscle.

Inclusion criteria

• Healthy men and women
• > 22 BMI < 28 kg/m2
• > 25 age < 46

Exclusion criteria

• History or clinical manifestation of cardiovascular disease or an elevated blood pressure (greater than 140/90 mm Hg)
• Abnormal resting ECG
• History or clinical manifestation of diabetes, cholelithiasis or any other significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic disorders, eating disorders or cancer
• History of stomach or intestinal surgery (except appendectomy) or major abdominal, thoracic or non-peripheral vascular surgery within one year prior to the randomization date
• Any disease or condition that seriously affects body weight and/or body composition
• Potassium level above the upper limit of normal at the screening visit confirmed by a test repeated within two weeks
• Hemoglobin, hematocrit, RBC, or iron level below the lower limit of normal at the screening visit confirmed by a test repeated within two weeks
• Evidence of active liver disease or ALT levels above 1.5 times the upper limit of normal
• Any history of pharmacologic treatment for a psychiatric disorder within one year prior to the randomization date or a history of more than one episode of a pharmacologic treatment for a psychiatric disorder within lifetime
• History of drug or alcohol abuse (up to 14 drinks a week are allowed) within the past two years
• Individuals who present with a BDI score of =15 at screening or baseline
• Short-term (less than a month) treatment with steroids within six months prior to the randomization date
• Treatment with steroids for more than a month within five years prior to the randomization date
• Regular use of other medications, except oral contraceptives
• Individuals who participated in the CALERIE Phase 1 studies
• A volunteer must be either be a never-smoker of tobacco products or an ex-smoker who quit completely at least 12 months prior to the screening visit
• Individuals who have magnetic metallic objects in their body
• Individuals who donated blood within 30 days prior to the randomization date
• Concurrent participation in any other interventional study
• Pregnant or breast-feeding women
• Individuals who were engaged in a regular program of physical fitness involving some kind of heavy physical activity (e.g., jogging, running or riding fast on a bicycle for 30 minutes or more) five or more times per week over the past year
• Unwilling to be assigned at random to the CR or control intervention
• Unwilling or unable to adhere to the rigors of the CR intervention over the entire two-year intervention
• Individuals who unable or unwilling to discontinue dietary supplements or adhere to the alcohol consumption restrictions during the study
• Unwilling or unable to adhere to the rigors of the data collection and clinical evaluation schedule